Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
NCT00630786
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
53
Enrollment
INDUSTRY
Sponsor class
Conditions
Colon Cancer
Colorectal Cancer
Rectal Cancer
Metastatic Colorectal Cancer
Oncology
Interventions
DRUG:
Panitumumab
DRUG:
Conatumumab
Sponsor
Amgen